$country= Comparative statistics by cancer registry - SurvCan

Comparative statistics by cancer registry

Registry: Comparative statistics by cancer site

Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site

(Shanghai, China, 1992-1995 cases followed-up until 2000)

Click on cancer site (ICD-10 code) for comparison
Site ICD-10 No. of cases included Complete FUIncomplete FU: loss to FU% with Complete FU at 5 yearsMedian FU (in months)
Alive/deadAt end of FUNo.%% lost to FU: years from diagnosis
No.%<11-33-5>5
C00Lip424197.612.40.00.02.40.097.666.2
C01-02Tongue20620398.531.50.00.50.50.599.066.1
C03-06Oral cavity28527897.572.50.01.40.40.798.261.9
C07-08Salivary gland18918698.431.60.01.10.50.098.474.1
C09Tonsil595694.935.13.41.70.00.094.947.8
C11Nasopharynx1060104598.6151.40.30.50.50.198.761.9
C12-13Hypopharynx3737100.000.00.00.00.00.0100.011.8
C15Oesophagus2988298099.780.30.10.10.10.099.86.8
C16Stomach117351165699.3790.70.20.20.20.199.49.3
C17Small intestine22922698.731.30.00.00.40.999.611.0
C18Colon4782473499.0481.00.10.30.40.299.231.4
C19-20Rectum3284324998.9351.10.10.30.40.399.232.5
C21Anus939197.822.20.02.20.00.097.828.7
C22Liver6954694299.8120.20.10.10.00.099.83.0
C23-24Gall bladder1383137899.650.40.20.10.10.099.63.8
C25Pancreas2242223899.840.20.10.10.00.099.93.0
C30-31Nose/Sinuses20019597.552.50.50.51.00.598.031.4
C32Larynx62462199.530.50.00.20.10.299.756.5
C33-34Lung141041405099.6540.40.00.20.10.199.76.5
C37-38Other thoracic organs40340099.330.70.00.20.00.599.811.2
C40-41Bone52352099.430.60.00.20.20.299.68.2
C43Melanoma skin11010999.110.90.90.00.00.099.140.9
C44Other skin47245997.2132.80.01.31.50.097.274.1
C47+C49Connective tissue48247598.571.50.10.80.40.298.865.4
C50Breast5184509498.3901.70.30.60.50.398.673.5
C51Vulva5454100.000.00.00.00.00.0100.049.8
C52Vagina454497.812.20.02.20.00.097.829.1
C53Cervix54854198.771.30.20.30.40.499.162.1
C54Corpus uteri73572598.6101.40.30.30.10.799.376.3
C55Uterus unspecified145145100.000.00.00.00.00.0100.011.6
C56Ovary1087107699.0111.00.20.40.20.299.230.2
C57Other female genital353497.112.92.90.00.00.097.156.1
C60Penis4949100.000.00.00.00.00.0100.073.6
C61Prostate63963499.250.80.20.20.20.299.425.9
C62Testis11311299.110.90.00.90.00.099.178.4
C64Kidney74372998.1141.90.20.80.50.498.539.6
C65Renal pelvis6767100.000.00.00.00.00.0100.061.4
C66Ureter686697.122.90.00.02.90.097.147.3
C67Urinary bladder1750172998.8211.20.20.10.60.399.161.0
C68Other urinary organs2626100.000.00.00.00.00.0100.031.6
C69Eye403997.512.50.00.02.50.097.566.7
C70-72Brain & nervous system1906188699.0201.00.00.30.50.299.214.4
C73Thyroid86884196.9273.10.31.11.20.597.477.9
C74Adrenal gland12311895.954.10.10.82.40.896.781.1
C75Other endocrine33032097.0103.00.30.91.20.697.675.0
C81Hodgkin lymphoma999798.022.01.00.00.01.099.065.5
C82-85+C96Non-Hodgkin lymphoma1271125899.0131.00.20.60.10.199.115.4
C90Multiple myeloma23022999.610.40.00.00.40.099.611.1
C91Lymphoid leukaemia338338100.000.00.00.00.00.0100.013.9
C92-94Myeloid leukaemia60560199.340.70.00.20.30.299.512.4
C95Leukaemia unspecified377377100.000.00.00.00.00.0100.03.6


Other tables available for this registry:
- Table1: Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table3: Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table5: Comparison of 5-year absolute and relative survival of cases diagnosed between 1988-1991 and 1992-1995 (Shanghai, China)




Registry chapter:


Consult the chapter in Cancer survival in developping countries (Volume II)